Skip to content

The impact of micronutrients and DHA on cognitive development of school-aged children: the NEMO studies.

The impact of micronutrients with or without DHA on cognitive development of school-aged children in Indonesia and South Australia. A randomized controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28087
Enrollment
780
Registered
2005-09-12
Start date
2003-08-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Randomized, controlled trial

Interventions

Children receiving fortified drink containing either: Micronutrient mix (iron, vit A, vit C, Vit B12, Vit B6 at one RDA, zinc at half RDA) or 88 mg DHA and 22 mg EPA or both or placebo

Sponsors

Unilever Netherlands BV
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children aged 6-9 yrs of age from six selected schools in urban Jakarta and 42 public schools in Southern Australia Parents or carers provided informed consent.

Exclusion criteria

Exclusion criteria: In the two study site: Children with severe physical and neurological health problems. No (intended) use of micronutrient/mineral and/or fatty acid supplements. In addition in Indonesia excluded are: children who are severely malnourished (Wt/Ht Z-score <=- 3SD) or severely anemic (hemoglobin < 8 g/L).

Design outcomes

Primary

MeasureTime frame
Cognitive performance (working memory, attention and concentration, perceptual speed, problem solving, executive function, learning and memory, school performance).

Secondary

MeasureTime frame
Biochemical indicators (blood iron status, zinc status, folate, vitamin B12) Fatty acids status (plasma EPA, DPA, DHA, ALA and total n-3 plasma mass) Growth (weight, height, body mass index).

Contacts

Public ContactJan Willem Klinken, van

Unilever Food and Health Research Institute (UFHRI), P.O. Box 114

Jan-Willem-van.Klinken@Unilever.com

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)